Back to Search
Start Over
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
- Source :
- Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
- Publication Year :
- 2020
- Publisher :
- Nature Portfolio, 2020.
-
Abstract
- All-trans retinoic acid - ATRA- is known to remodulate the stroma of pancreatic cancer in mice. Here, the authors carried out a Phase Ib trial in pancreatic patients and show that ATRA in combination with chemotherapy is a safe potential treatment for patients with advanced pancreatic cancer, and demonstrate a stromal modulatory effect.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 11
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7c7d3ad82a9e4375ae3a8da492b9ac27
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-020-18636-w